Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
afrol News - May 8, 2008
Apotex is the first company to provide this medicine to Africa under the provisions of the Canadian Access to Medicines Regime (CAMR).
The CAMR provides a mechanism for developing countries to address critical healthcare needs by importing less expensive generic versions of patented drugs. After going through a three-year process, Apotex has got to a point where its drug can go to thousands in Africa.
Apotex is the only company in Canada to have worked through the complicated CAMR process. The Generic Pharmaceutical Industry has recommended that the Federal Government simplify the process of getting urgently needed drugs to Africa.
Apo Triavir, which has been evaluated and approved under the provision of the CAMR by Health Canada, is a combination of 300 mg Zidovudine, 150 mg Lamivudine and 200 mg Nevirapine. Triavir fully conforms to all Health Canada regulations and requirements for marketing a drug in the Canadian healthcare system. As per Canadian regulations, the product can only be exported to eligible countries under CAMR and cannot be sold in Canada until the relevant patents expire.
The price quoted in the tender has been pegged at US 19.5 cents per tablet. The three separate AIDS brand products would cost around US $6.00 per dose if bought individually.
"If other critical medicines are to go to Africa in a reasonable timeframe, the federal government must change the CAMR Legislation," Apotex President, Jack Kay said in press statement.
"CAMR is unworkable as it now stands. Apotex decided to do this because it was the right thing to do for the people dying from AIDS in Africa."
The Apotex Group has 6,000 employees in Canada and exports close to 300 quality lower cost medicines to 115 countries.
080508
AO080501
Copyright © 2008 - afrol News. All rights reserved. Reproducing or buying afrol News' articles. Reproduction of this article (other than one copy for personal reference) must be cleared through afrol News.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .